What does PROXY PHARMA do?

PROXY PHARMA is a pharmacy in Beauvechain. Private Limited, started on 7 April 2017, 1 establishment.

What is the address of PROXY PHARMA?

The registered office of PROXY PHARMA is located at Rue des Salamandres,T.-la-G. 2, 1320 Beauvechain.

Is PROXY PHARMA still active?

Yes. According to the CBE (29 October 2026) PROXY PHARMA is active, legal situation “Normale toestand”, started on 7 April 2017.

Is PROXY PHARMA registered on Peppol?

Yes, PROXY PHARMA is registered on the Peppol network with ID 0208:0673992721.

What is the enterprise number of PROXY PHARMA?

The enterprise number of PROXY PHARMA is BE0673992721.

When was PROXY PHARMA founded?

PROXY PHARMA was founded on 7 April 2017.

Who are the directors of PROXY PHARMA?

According to the 2025 annual accounts, the directors of PROXY PHARMA are: MALIKA HASNAOUI.

Is PROXY PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 April 2017; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PROXY PHARMA make in 2025?

PROXY PHARMA posted a profit after taxes of € 52,432 in financial year 2025.

What is the revenue of PROXY PHARMA?

As a small company, PROXY PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 214,043.

How much does an employee at PROXY PHARMA earn?

The average wage cost per full-time employee at PROXY PHARMA was € 34,400 in 2025: staff costs of € 62,002 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PROXY PHARMA have?

According to the 2025 annual accounts, PROXY PHARMA has 1.8 full-time equivalents (FTE).

PROXY PHARMA (Private Limited) - Beauvechain

Dossier PROXY PHARMA, printed on 29 October 2026 from databakkes.be/en/0673992721/proxy-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Figures corrected NBB

Corrected annual account filed for 2022.

Financials

Financial year 2025

PROXY PHARMA from Beauvechain, company number BE0673992721, closed financial year 2025 with a result of € 52,432 after tax. For that financial year PROXY PHARMA recorded a gross margin of € 214,043 and equity of € 21,794. Compared with financial year 2024, the result moved from € 8,200 to € 52,432. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.

What it is worth Healthy

€ 21,794

▼ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 52,432

▲ € 44,233 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 220,595

▲ 12% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 60,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

1.8

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 62,002

▲ 3% vs 2024

€ 34,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 38,556

▼ 35% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 394,042

▼ 9% vs 2024

€ 37,557 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 142,029

▼ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 17,821

▲ 62% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 205,543 Gross margin 2022: € 205,543 First fiscal year in the series	€ 189,045 Gross margin 2023: € 189,045 ▼ 8% vs 2022 (€ 205,543) Unfavourable step	€ 173,544 Gross margin 2024: € 173,544 ▼ 8% vs 2023 (€ 189,045) Unfavourable step	€ 214,043 Gross margin 2025: € 214,043 ▲ 23% vs 2024 (€ 173,544) Favourable step	▲ 23%
Profit after taxes	€ 79,265 Profit after taxes 2022: € 79,265 First fiscal year in the series	€ 57,355 Profit after taxes 2023: € 57,355 ▼ 28% vs 2022 (€ 79,265) Unfavourable step	€ 8,200 Profit after taxes 2024: € 8,200 ▼ 86% vs 2023 (€ 57,355) Unfavourable step	€ 52,432 Profit after taxes 2025: € 52,432 ▲ € 44,233 vs 2024 (€ 8,200) Favourable step	▲ € 44,233
Equity	€ 39,807 Equity 2022: € 39,807 First fiscal year in the series	€ 71,163 Equity 2023: € 71,163 ▲ 79% vs 2022 (€ 39,807) Favourable step	€ 29,362 Equity 2024: € 29,362 ▼ 59% vs 2023 (€ 71,163) Unfavourable step	€ 21,794 Equity 2025: € 21,794 ▼ 26% vs 2024 (€ 29,362) Unfavourable step	▼ 26%
Total debts	€ 714,361 Total debts 2022: € 714,361 First fiscal year in the series	€ 556,685 Total debts 2023: € 556,685 ▼ 22% vs 2022 (€ 714,361) Favourable step	€ 767,014 Total debts 2024: € 767,014 ▲ 38% vs 2023 (€ 556,685) Unfavourable step	€ 731,095 Total debts 2025: € 731,095 ▼ 5% vs 2024 (€ 767,014) Favourable step	▼ 5%
Cash	€ 253,832 Cash 2022: € 253,832 First fiscal year in the series	€ 193,788 Cash 2023: € 193,788 ▼ 24% vs 2022 (€ 253,832) Unfavourable step	€ 197,586 Cash 2024: € 197,586 ▲ 2% vs 2023 (€ 193,788) Favourable step	€ 220,595 Cash 2025: € 220,595 ▲ 12% vs 2024 (€ 197,586) Favourable step	▲ 12%
Land & buildings	€ 131,792 Land & buildings 2022: € 131,792 First fiscal year in the series	€ 122,794 Land & buildings 2023: € 122,794 ▼ 7% vs 2022 (€ 131,792) Unchanged	€ 317,514 Land & buildings 2024: € 317,514 ▲ 159% vs 2023 (€ 122,794) Unchanged	€ 292,489 Land & buildings 2025: € 292,489 ▼ 8% vs 2024 (€ 317,514) Unchanged	▼ 8%
Retained profit	€ 21,207 Retained profit 2022: € 21,207 First fiscal year in the series	€ 52,563 Retained profit 2023: € 52,563 ▲ 148% vs 2022 (€ 21,207) Favourable step	€ 10,762 Retained profit 2024: € 10,762 ▼ 80% vs 2023 (€ 52,563) Unfavourable step	€ 3,194 Retained profit 2025: € 3,194 ▼ 70% vs 2024 (€ 10,762) Unfavourable step	▼ 70%
Dividend	€ 61,000 Dividend 2022: € 61,000 First fiscal year in the series	€ 26,000 Dividend 2023: € 26,000 ▼ 57% vs 2022 (€ 61,000) Unchanged	€ 50,000 Dividend 2024: € 50,000 ▲ 92% vs 2023 (€ 26,000) Unchanged	€ 60,000 Dividend 2025: € 60,000 ▲ 20% vs 2024 (€ 50,000) Unchanged	▲ 20%
Bank debt	€ 283,466 Bank debt 2022: € 283,466 First fiscal year in the series	€ 252,790 Bank debt 2023: € 252,790 ▼ 11% vs 2022 (€ 283,466) Favourable step	€ 432,360 Bank debt 2024: € 432,360 ▲ 71% vs 2023 (€ 252,790) Unfavourable step	€ 394,042 Bank debt 2025: € 394,042 ▼ 9% vs 2024 (€ 432,360) Favourable step	▼ 9%
Balance sheet total	€ 754,169 Balance sheet total 2022: € 754,169 First fiscal year in the series	€ 627,848 Balance sheet total 2023: € 627,848 ▼ 17% vs 2022 (€ 754,169) Unchanged	€ 796,376 Balance sheet total 2024: € 796,376 ▲ 27% vs 2023 (€ 627,848) Unchanged	€ 752,890 Balance sheet total 2025: € 752,890 ▼ 5% vs 2024 (€ 796,376) Unchanged	▼ 5%
Employees (FTE)	1.4 Employees (FTE) 2022: 1.4 First fiscal year in the series	1.3 Employees (FTE) 2023: 1.3 ▼ 0.1 vs 2022 (1.4) Unchanged	1.7 Employees (FTE) 2024: 1.7 ▲ 0.4 vs 2023 (1.3) Unchanged	1.8 Employees (FTE) 2025: 1.8 ▲ 0.1 vs 2024 (1.7) Unchanged	▲ 0.1

Key figures of PROXY PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PROXY PHARMA?

What happened at PROXY PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 16, 2026 New annual accounts for financial year 2025: profit of € 52,432 (▲ € 44,233 vs 2024). Source: NBB ↗
Apr 7, 2017 New establishment in Sint-Joost-ten-Node. KBO
Apr 7, 2017 Start of the company according to the CBE. KBO
2017 MALIKA HASNAOUI became a director. NBB

In short

From € 79,265 profit in 2022 to € 52,432 profit in 2025.

Paid € 52,318 in corporate taxes since 2022.

Best year ever: 2022, with € 79,265 profit.

On average € 118,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

MALIKA HASNAOUI

PROXY PHARMA

Behind PROXY PHARMA is MALIKA HASNAOUI.

Directors

According to the 2025 annual accounts

MALIKA HASNAOUI

Administrator-manager

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Salamandres,T.-la-G. 2

1320 Beauvechain

2.264.578.826

Willemsstraat 45b

1210 Sint-Joost-ten-Node

Active since 7 April 2017

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0673.992.721
VAT number: BE 0673.992.721
Registered office: Rue des Salamandres,T.-la-G. 2, 1320 Beauvechain
Names & denominations: PROXY PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 7 April 2017
Peppol: Active · Active since 2 Dec 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗